Characteristics of patients with difficult-to-treat rheumatoid arthritis: a descriptive retrospective cohort study.
Antirheumatic agents
Fibromyalgia
JAK inhibitors
Rheumatoid arthritis
Journal
Advances in rheumatology (London, England)
ISSN: 2523-3106
Titre abrégé: Adv Rheumatol
Pays: England
ID NLM: 101734172
Informations de publication
Date de publication:
06 Aug 2024
06 Aug 2024
Historique:
received:
03
04
2024
accepted:
25
07
2024
medline:
7
8
2024
pubmed:
7
8
2024
entrez:
6
8
2024
Statut:
epublish
Résumé
In 2021, an EULAR task force published a definition of difficult-to-treat rheumatoid arthritis (D2T RA). Our current knowledge of D2T RA with the EULAR definition is based on European and Asian cohorts, and no North American cohort has yet to be published. The aim of this study was to compare D2T RA patients to non-D2T RA who are good responders to advanced therapy, and to describe their evolution in an university health center patient cohort. This is a retrospective single centre study of the medical records of all adults with RA on at least one biologic or target synthetic DMARD (b/tsDMARD). D2T RA group was defined according to the EULAR definition of D2T RA. The non-D2T RA group was defined as a b/tsDMARD good responder who had low-disease activity or remission for at least one year on 1 or 2 b/tsDMARD mechanism of action. We compared the patients' comorbidities, and history of b/tsDMARD use. Descriptive statistics and proportions were calculated. Kaplan-Meier analysis with log-rank test was used to estimate and compare median survival. Among the 417 patients, 101 (24%) were D2T RA and 316 (76%) were non-D2T RA. D2T RA group was slightly younger (63 ± 9 years versus 65 ± 12 years, p = 0.045), more likely to have concomitant non-inflammatory pain (28% versus 8%, p < 0.0001) and to discontinue at least one b/tsDMARD due to intolerance (39% versus 10%, p < 0.0001). In the D2T RA group, JAK inhibitors were associated with longer drug continuation when used as the third b/tsDMARD. Fewer patients were using corticosteroid at their most recent follow-up in this Canadian cohort compared to others (16% versus from 29 to 74%). Concomitant non-inflammatory pain was more prevalent in D2T RA patients compared to b/tsDMARD good responder non-D2T RA patients. Steroid-sparing strategies is possible even in D2T RA patients. Future prospective research may compare JAK inhibitors with other mechanisms of action in D2T RA.
Sections du résumé
BACKGROUND
BACKGROUND
In 2021, an EULAR task force published a definition of difficult-to-treat rheumatoid arthritis (D2T RA). Our current knowledge of D2T RA with the EULAR definition is based on European and Asian cohorts, and no North American cohort has yet to be published. The aim of this study was to compare D2T RA patients to non-D2T RA who are good responders to advanced therapy, and to describe their evolution in an university health center patient cohort.
METHODS
METHODS
This is a retrospective single centre study of the medical records of all adults with RA on at least one biologic or target synthetic DMARD (b/tsDMARD). D2T RA group was defined according to the EULAR definition of D2T RA. The non-D2T RA group was defined as a b/tsDMARD good responder who had low-disease activity or remission for at least one year on 1 or 2 b/tsDMARD mechanism of action. We compared the patients' comorbidities, and history of b/tsDMARD use. Descriptive statistics and proportions were calculated. Kaplan-Meier analysis with log-rank test was used to estimate and compare median survival.
RESULTS
RESULTS
Among the 417 patients, 101 (24%) were D2T RA and 316 (76%) were non-D2T RA. D2T RA group was slightly younger (63 ± 9 years versus 65 ± 12 years, p = 0.045), more likely to have concomitant non-inflammatory pain (28% versus 8%, p < 0.0001) and to discontinue at least one b/tsDMARD due to intolerance (39% versus 10%, p < 0.0001). In the D2T RA group, JAK inhibitors were associated with longer drug continuation when used as the third b/tsDMARD. Fewer patients were using corticosteroid at their most recent follow-up in this Canadian cohort compared to others (16% versus from 29 to 74%).
CONCLUSION
CONCLUSIONS
Concomitant non-inflammatory pain was more prevalent in D2T RA patients compared to b/tsDMARD good responder non-D2T RA patients. Steroid-sparing strategies is possible even in D2T RA patients. Future prospective research may compare JAK inhibitors with other mechanisms of action in D2T RA.
Identifiants
pubmed: 39107865
doi: 10.1186/s42358-024-00396-6
pii: 10.1186/s42358-024-00396-6
doi:
Substances chimiques
Antirheumatic Agents
0
Biological Products
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
55Subventions
Organisme : Fondation CHU de Québec
ID : N/A
Organisme : Fonds de Recherche du Québec - Santé
ID : Career award
Organisme : Canada Research Chairs
ID : N/A
Informations de copyright
© 2024. The Author(s).
Références
Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021;41(5):863–77.
doi: 10.1007/s00296-020-04731-0
pubmed: 33175207
Canada, AAo. The impact of arthritis in Canada: today and over the next 30 years. 2011. http://www.ergoresearchcom/wp-content/uploads/2012/04/Impact%2520on%2520arthrisis%2520in%2520Canada_Today%2520and%2520over%2520the%2520next%252030%2520yearspdf .
Smolen JS. Treat to target in Rheumatology: a historical account on occasion of the 10th anniversary. Rheum Dis Clin North Am. 2019;45(4):477–85.
doi: 10.1016/j.rdc.2019.07.001
pubmed: 31564291
de Hair MJH, Jacobs JWG, Schoneveld JLM, van Laar JM. Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford). 2018;57(7):1135–44.
pubmed: 29029308
Takanashi S, Kaneko Y, Takeuchi T. Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice. Rheumatology (Oxford). 2021;60(11):5247–56.
doi: 10.1093/rheumatology/keab209
pubmed: 33682890
Roodenrijs NMT, van der Goes MC, Welsing PMJ, Tekstra J, Lafeber F, Jacobs JWG, et al. Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease. Rheumatology (Oxford). 2021;60(8):3778–88.
doi: 10.1093/rheumatology/keaa860
pubmed: 33331946
Roodenrijs NMT, Welsing PMJ, van der Goes MC, Tekstra J, Lafeber F, Jacobs JWG, et al. Health care utilisation and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study. Rheumatology (Oxford). 2021;60(10):4681–4690. https://doi.org/10.1093/rheumatology/keab078
Kearsley-Fleet L, Davies R, De Cock D, Watson KD, Lunt M, Buch MH, et al. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018;77(10):1405–12.
doi: 10.1136/annrheumdis-2018-213378
pubmed: 29980575
Novella-Navarro M, Plasencia C, Tornero C, Navarro-Compan V, Cabrera-Alarcon JL, Peiteado-Lopez D, et al. Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis. Arthritis Res Ther. 2020;22(1):284.
doi: 10.1186/s13075-020-02354-1
pubmed: 33298140
pmcid: 7724866
Ochi S, Mizoguchi F, Nakano K, Tanaka Y. Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry. Clin Exp Rheumatol. 2022;40(1):86–96.
doi: 10.55563/clinexprheumatol/g33ia5
pubmed: 33635223
Roodenrijs NMT, Hamar A, Kedves M, Nagy G, van Laar JM, van der Heijde D, et al. Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD open. 2021;7(1):e001512.
Roodenrijs NMT, Kedves M, Hamar A, Nagy G, van Laar JM, van der Heijde D, et al. Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD open. 2021;7(1):e001511.
Roodenrijs NMT, de Hair MJH, van der Goes MC, Jacobs JWG, Welsing PMJ, van der Heijde D, et al. Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Ann Rheum Dis. 2018;77(12):1705–9.
doi: 10.1136/annrheumdis-2018-213687
pubmed: 30194273
Nagy G, Roodenrijs NMT, Welsing PM, Kedves M, Hamar A, van der Goes MC, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80(1):31–5.
doi: 10.1136/annrheumdis-2020-217344
pubmed: 33004335
Nagy G, Roodenrijs NMT, Welsing PMJ, Kedves M, Hamar A, van der Goes MC, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2022;81(1):20–33.
doi: 10.1136/annrheumdis-2021-220973
pubmed: 34407926
Leon L, Madrid-Garcia A, Lopez-Viejo P, Gonzalez-Alvaro I, Novella-Navarro M, Freites Nunez D, et al. Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease. RMD open. 2023;9(1):e002842.
Tan Y, Buch MH. ‘Difficult to treat’ rheumatoid arthritis: current position and considerations for next steps. RMD open. 2022;8(2):e002387.
Watanabe R, Hashimoto M, Murata K, Murakami K, Tanaka M, Ohmura K, et al. Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort. Immunological Med. 2021:1–10.
Dey M, Nagy G, Nikiphorou E. Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin? Rheumatology (Oxford). 2023;62(5):1773–9.
doi: 10.1093/rheumatology/keac584
pubmed: 36205537
Conran C, Kolfenbach J, Kuhn K, Striebich C, Moreland L. A review of difficult-to-treat rheumatoid arthritis: definition, clinical presentation, and management. Curr Rheumatol Rep. 2023;25(12):285–94.
doi: 10.1007/s11926-023-01117-6
pubmed: 37776482
Roodenrijs NMT, van der Goes MC, Welsing PMJ, van Oorschot EPC, Nikiphorou E, Nijhof NC, et al. Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study. Rheumatology (Oxford). 2021;60(11):5105–16.
doi: 10.1093/rheumatology/keab130
pubmed: 33560301
Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–39.
doi: 10.1002/acr.24596
Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–99.
doi: 10.1136/annrheumdis-2019-216655
pubmed: 31969328
Haraoui B, Jovaisas A, Bensen WG, Faraawi R, Kelsall J, Dixit S, et al. Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population. RMD open. 2015;1(1):e000078.
doi: 10.1136/rmdopen-2015-000078
pubmed: 26509071
pmcid: 4612699
Andersen KM, Schieir O, Valois MF, Bartlett SJ, Bessette L, Boire G, et al. A bridge too far? Real-world practice patterns of early glucocorticoid use in the Canadian early arthritis cohort. ACR Open Rheumatol. 2022;4(1):57–64.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.
Michitsuji T, Fukui S, Morimoto S, Endo Y, Nishino A, Nishihata S, et al. Clinical and ultrasound features of difficult-to-treat rheumatoid arthritis: a multicenter RA ultrasound cohort study. Scand J Rheumatol. 2024;53(2):123–9.
doi: 10.1080/03009742.2023.2277542
pubmed: 38085537
Garcia-Salinas R, Sanchez-Prado E, Mareco J, Ronald P, Ruta S, Gomez R, et al. Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations. Rheumatol Int. 2023;43(10):1821–8.
doi: 10.1007/s00296-023-05349-8
pubmed: 37269430
Zangi HA, Ndosi M, Adams J, Andersen L, Bode C, Bostrom C, et al. EULAR recommendations for patient education for people with inflammatory arthritis. Ann Rheum Dis. 2015;74(6):954–62.
doi: 10.1136/annrheumdis-2014-206807
pubmed: 25735643
Novella-Navarro M, Ruiz-Esquide V, Torres-Ortiz G, Chacur CA, Tornero C, Fernandez-Fernandez E, et al. A paradigm of difficult-to-treat rheumatoid arthritis: subtypes and early identification. Clin Exp Rheumatol. 2023;41(5):1114–9.
pubmed: 36377568
Takanashi S, Kaneko Y, Takeuchi T. Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80(11):1491–3.
doi: 10.1136/annrheumdis-2021-220315
pubmed: 33962961
Ochi S, Sonomoto K, Nakayamada S, Tanaka Y. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. Arthritis Res Ther. 2022;24(1):61.
doi: 10.1186/s13075-022-02744-7
pubmed: 35232462
pmcid: 8886884
Watanabe R, Okano T, Gon T, Yoshida N, Fukumoto K, Yamada S, et al. Difficult-to-treat rheumatoid arthritis: current concept and unsolved problems. Front Med (Lausanne). 2022;9:1049875.
doi: 10.3389/fmed.2022.1049875
pubmed: 36353219
Hecquet S, Combier A, Steelandt A, Pons M, Wendling D, Molto A, et al. Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital. Rheumatology (Oxford). 2023;62(12):3866–74.
doi: 10.1093/rheumatology/kead143
pubmed: 36961324
Simon LS, Taylor PC, Choy EH, Sebba A, Quebe A, Knopp KL, et al. The Jak/STAT pathway: a focus on pain in rheumatoid arthritis. Semin Arthritis Rheum. 2021;51(1):278–84.
doi: 10.1016/j.semarthrit.2020.10.008
pubmed: 33412435
Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging Clinical Data. J Inflamm Res. 2020;13:519–31.
doi: 10.2147/JIR.S219586
pubmed: 32982367
pmcid: 7500842
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(4):316–26.
doi: 10.1056/NEJMoa2109927
pubmed: 35081280
US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. 2022. https://www.fdagov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death . Accessed 31 Jan 2022.
European Medicines Agency, Xeljanz. 2022. https://www.emaeuropaeu/en/medicines/human/referrals/xeljanz#:~:text=On%2014%20November%20EMA%20concluded,high%20risk%20of%20blood%20clots . Accessed 31 Jan 2022.
Giollo A, Zen M, Larosa M, Astorri D, Salvato M, Calligaro A, et al. Early characterization of difficult-to-treat rheumatoid arthritis by suboptimal initial management: a multicentre cohort study. Rheumatology (Oxford). 2023;62(6):2083–9.
doi: 10.1093/rheumatology/keac563
pubmed: 36190344
Carbonell-Bobadilla N, Soto-Fajardo C, Amezcua-Guerra LM, Batres-Marroquin AB, Vargas T, Hernandez-Diazcouder A, et al. Patients with seronegative rheumatoid arthritis have a different phenotype than seropositive patients: a clinical and ultrasound study. Front Med (Lausanne). 2022;9:978351.
doi: 10.3389/fmed.2022.978351
pubmed: 36052337
Roodenrijs NMT, Welsing PMJ, van der Goes MC, Jacobs JW, van der Heijde D, van Laar JM, et al. Response to: ‘Correspondence on ‘EULAR definition of difficult-to-treat rheumatoid arthritis’’ by Novella-Navarro. Ann Rheum Dis. 2023; 82(3):e56.
Novella-Navarro M, Plasencia-Rodriguez C, Tornero C, Navarro-Compan V, Cabrera-Alarcon JL, Peiteado D, et al. Correspondence on: ‘EULAR definition of difficult-to-treat rheumatoid arthritis’. Ann Rheum Dis. 2023;82(3):e55.